What is APVO's earnings growth forecast for 2028-2028?
(NASDAQ: APVO) Aptevo Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.13%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.27%.
Aptevo Therapeutics's earnings in 2025 is -$24,025,000.
In 2028, APVO is forecast to generate -$234,757,345 in earnings, with the lowest earnings forecast at -$234,757,345 and the highest earnings forecast at -$234,757,345.
What is APVO's forecast return on equity (ROE) for 2025-2028?
(NASDAQ: APVO) forecast ROE is -3,598.37%, which is considered weak.
What is APVO's Earnings Per Share (EPS) forecast for 2028-2028?
(NASDAQ: APVO) Aptevo Therapeutics's current Earnings Per Share (EPS) is $1,508.40. In 2028, APVO's EPS is forecast to hit -$71.40 (min: -$71.40, max: -$71.40).
What is APVO's forecast return on assets (ROA) for 2025-2028?
(NASDAQ: APVO) forecast ROA is -1,502.54%, which is lower than the forecast US Biotechnology industry average of 47.84%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.